63598-71-0

Usage

Chemical structure

1H-1,2,4-triazole is a heterocyclic organic compound with a five-membered ring consisting of three nitrogen atoms and two carbon atoms.

Physical state

It is a clear, colorless liquid.

Applications in pharmaceutical industry

Widely used as a building block for the synthesis of various drugs and pharmaceutical compounds.

Applications in agriculture

Used as a fungicide.

Applications in polymer and plastic production

Utilized in the production of polymers and plastics.

Use as a stabilizer

Employed as a stabilizer for peroxide-based compounds.

Use as a corrosion inhibitor

Acts as a corrosion inhibitor.

Unique structure

1H-1,2,4-triazole has a unique structure that contributes to its versatile properties.

Importance in various industries

Due to its versatile properties, 1H-1,2,4-triazole is an important chemical compound in the pharmaceutical, agricultural, polymer, and corrosion inhibition industries.

Upstream product

• 584-13-4 4-amino-1,2,4-triazole 
• 108-67-8 1,3,5-trimethyl-benzene 
• 24994-60-3 1-amino-1,2,4-triazole 
• 98-88-4 benzoyl chloride 
• 1015603-47-0 5-benzoyl-3-ethoxycarbonyl-1-methyl-6-methylthio-1,2-dihydropyridin-2-one 
• 122709-89-1 Phenyl-[(Z)-[1,2,4]triazol-4-ylimino]-acetic acid 
• 288-88-0 1,2,4-Triazole 

Downstream Products

• 122583-48-6 1-Benzylideneamino-1H-1,2,4-triazole 
• 72796-81-7 2-(Diethoxy-phosphoryl)-3-p-tolyl-3-[1,2,4]triazol-1-yl-propionic acid ethyl ester 
• 72796-75-9 2-[(4-Chloro-phenyl)-[1,2,4]triazol-1-yl-methyl]-3-oxo-butyric acid ethyl ester 
• 72796-74-8 3-(4-Chloro-phenyl)-2-dimethylcarbamoyl-3-[1,2,4]triazol-1-yl-propionic acid methyl ester 
• 72811-86-0 2-(4-Chloro-benzoyl)-3-phenyl-3-[1,2,4]triazol-1-yl-propionic acid methyl ester 
• 72796-83-9 4-(4-Chloro-phenyl)-3-(toluene-4-sulfonyl)-4-[1,2,4]triazol-1-yl-butan-2-one 
• 72796-82-8 3-(4-Chloro-phenyl)-2-(toluene-4-sulfonyl)-3-[1,2,4]triazol-1-yl-propionic acid methyl ester 
• 66760-19-8 4-(2'-hydroxyethyl)-1,2,4-triazole 
• 72796-76-0 3-(Phenyl-[1,2,4]triazol-1-yl-methyl)-pentane-2,4-dione 
• 65-85-0 benzoic acid 
• 63935-98-8 1-allyl-[1,2,4]triazole 
• 99091-96-0 4-allyl-1,2,4-triazole 
• 1616093-49-2 C₅₂H₅₇N₈O₁₀P 
• 1616093-49-2 C₅₂H₅₇N₈O₁₀P 

Relevant academic research and scientific papers

Heterocyclization of 3-(R-amino)-3-methylthio-1-phenylpropenones and 5-benzoyl-6-methylthio-1,2-dihydropyridin-2-ones with 1,2- and 1,3-dinucleophilic reagents

The interaction of 3-(R-amino)-3-methylthio-1-phenylpropenones and 1-alkyl-5-benzoyl-3-ethoxy-carbonyl-6-methylthio-1,2-dihydropyridin-2-ones with N,N- and N,C-1,2- and 1,3-dinucleophiles proceeded regioselectively by [3+2] and [3+3] cyclocondensation with the formation of derivatives of pyrazole, benzimidazo[1,2-a]-pyridine, benzimidazo[1,2-a]pyrimidine, imidazo[1,2-a] pyrimidine, [1,2,4]triazolo[4,3-b]pyridazine, and 6,7-dihydro-2H-pyrazolo[3,4-b] pyridine. The regioselectivity of the reactions carried out was analyzed.

Substituted amino methyl factor Xa inhibitors

The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Oxazole PPAR antagonist

A method is disclosed for rational design of a PPAR, FXR, LXR-alpha, or LXR-beta antagonist comprising chemical modification of a PPAR, FXR, LXR-alpha, or LXR-beta agonist to: a) prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist bound position. Preferably, little or no additional changes are made in the structure of the agonist so that the resulting antagonist is a close structural analogue of the agonist. Specific examples of PPAR gamma antagonists designed and prepared using the method of this invention are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where in Formula (I) X is O, S, or NH; and R is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, phenyl, or —CH2OCH3and wherein in Formula (II) X is C or N; and R is methyl, ethyl, n-propyl, i-propyl, —CH2OCH3, or —CO2CH3.

Heteroaryl-phenyl substituted factor Xa inhibitors

The present application describes heteroaryl-phenyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of factor Xa.

Heteroaryl- phenyl heterobicyclic factor Xa inhibitors

The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

The 1,2,4-triazolyl cation: Thermolytic and photolytic studies

The generation of the 1,2,4-triazolyl cation (1) has been attempted by the thermolysis and photolysis of 1-(1,2,4-triazol-4-yl)-2,4,6-trimethylpyridinium tetrafluoroborate (2) and the thermolysis of 1- and 4-diazonium-1,2,4-triazoles, using mainly mesitylene as the trapping agent. Thermolysis of 2 gave mostly 1,2,4-triazole, together with 3-(1,2,4-triazol-4-yl)-2,4,6-trimethylpyridine, 4-(1,2,4-triazol-4-ylmethyl)-2,6-dimethylpyridine, and 4-(2,4,6-trimethylbenzyl)-2,6-dimethylpyridine. Thermolysis, of each of the diazonium salts in the presence of mesitylene again gave mainly triazole together with very low yields of 1-(1,2,4-triazol-1-yl)-2,4,6-trimethylbenzene and the corresponding -4-yl isomer in about the same ratio. On the other hand, photolysis of 2 in mesitylene gave mainly 1-(1,2,4-triazol-1-yl)-2,4,6-trimethylbenzene. A photoinduced electron transfer from mesitylene to 2 has been observed and preliminary laser flash photolyses of 2 and the corresponding 2,4,6-triphenylpyridinium salt have been carried out. The observed transients are explained as arising from the first excited states of the pyridinium salts rather than from 1. Ab initio MO calculations are reported and indicate that the predicted electronic ground-state of the triazolyl cation is a triplet state of B1 symmetry with five π electrons, which corresponds to a diradical cation (1c). Possible mechanisms for the formation of the various products are proposed.

Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa

The present application describes inhibitors of factor Xa of formula I: or pharmaceutically acceptable salt forms thereof, wherein W, W1, W2, and W3may be N or C and J, Ja, and Jbcombine to form a substituted carbocycle or heterocycle.

6-membered aromatics as factor Xa inhibitors

The present application describes 6-membered aromatics of formula I: or pharmaceutically acceptable salt forms thereof, wherein D may be CH2NH2 or C(=NH)NH2, which are useful as inhibitors of factor Xa.

α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors

The present application describes m-amidino phenyl analogs of formula I: wherein D can be amidino and E can be phenyl, which are useful as inhibitors of factor Xa.

N-(AMIDINOPHENYL) CYCLOUREA ANALOGS AS FACTOR XA INHIBITORS

The present application describes N-(amidinophenyl)cyclourea analogs of formula I: STR1 which are useful as inhibitors of factor Xa.